CEO
MediMabBio
The startup develops cytokine-antibody fusion proteins to create first-in-class immuno-oncology drugs that specifically target advanced solid tumors. This approach aims to enhance the efficacy of cancer immunotherapy by overcoming the limitations of existing treatment options.
- Biotechnology
Updated 21 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops cytokine-antibody fusion proteins to create first-in-class immuno-oncology drugs that specifically target advanced solid tumors. This approach aims to enhance the efficacy of cancer immunotherapy by overcoming the limitations of existing treatment options.